Physician profile
Patrick Durbin
NPI 1023079928
$695.41
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $80.17 · 2021: $169 · 2022: $52.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $241.56 | 2019-2022 | |
| Glaxosmithkline, LLC. | $147.48 | 2019-2021 | |
| Allergan, INC. | $125.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.61 | 2021 | |
| Novo Nordisk INC | $27.83 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $26.74 | 2021 | |
| Amarin Pharma, INC. | $25.01 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.02 | 2022 | |
| Daiichi Sankyo INC. | $19.19 | 2021 | |
| Pfizer INC. | $14.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Durbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.